Prophylactic tracheotomy and lung cancer resection in patient with low predictive pulmonary function: a randomized clinical trials.

Marc Filaire, Marie M Tardy, Ruddy Richard, Adel Naamee, Jean Baptiste Chadeyras, Valence Da Costa, Patrick Bailly, Nathanaël Eisenmann, Bruno Pereira, Patrick Merle, Géraud Galvaing

Journal: Chinese clinical oncology 2016;4(4):40

PMID: 26730752

Abstract

BACKGROUND

Whether prophylactic tracheotomy can shorten the duration of mechanical ventilation (MV) in high risk patients eligible for lung cancer resection. The objective was to compare duration of MV and outcome in 39 patients randomly assigned to prophylactic tracheotomy or control.

METHODS

Prospective randomized controlled, single-center trial (ClinicalTrials.gov Identifier: NCT01053624). The primary outcome measure was the cumulative number of MV days after operation until discharge. The secondary outcome measures were the 60 days mortality rate, the ICU and the hospital length of stay, the incidence of postoperative respiratory, cardiac and general complications, the reventilation rate, the need of noninvasive ventilation (NIV), the need of a tracheotomy in control group and the tracheal complications.

RESULTS

The duration of MV was not significantly different between the tracheotomy group (3.5±6 days) and the control group (4.7±9.3 days) (P=0.54). Among patients needing prolonged MV >4 days, tracheotomy patients had a shortened duration of MV than control patients (respectively 11.4±7.1 and 20.4±9.6 days, P=0.04). The rate of respiratory complications were significantly lower in the tracheotomy group than in the control group (28% vs. 51%, P=0.03). Six patients (15%) needed a postoperative tracheotomy in the control group because of a prolonged MV >7 days. Tracheotomy was associated with a reduced need of NIV (P=0.04). There was no difference in 60-day mortality rate, cardiac complications, intensive care unit and hospital length of stay. No death was related with the tracheotomy.

CONCLUSIONS

Prophylactic tracheotomy in patients with ppo FEV1 <50% who underwent thoracotomy for lung cancer resection provided benefits in terms of duration of prolonged MV and respiratory complications but was not associated with a decreased mortality rate, ICU and hospital length of stay and non-respiratory complications.

Address: Department of Thoracic Surgery, Jean Perrin Cancer Center, 58 Rue Montalembert, BP 392, 63011 Clermont-Ferrand, France. [email protected].; Departement of Thoracic Surgery, Jean Perrin Cancer Center, 63011 Clermont-Ferrand, France.; INRA, Unité Mixte de Recherche 1019, Centre de Recherche en Nutrition Humaine Auvergne, Clermont-Ferrand, France; Department of Sport Medicine and Functional Explorations, Gabriel Montpied University Hospital, 63003 Clermont-Ferrand, France.; Departement of Anesthesiology, Jean Perrin Cancer Center, 63011 Clermont-Ferrand, France.; University Hospital Clermont-Ferrand, Biostatistics Unit (DRCI), Clermont-Ferrand, France.; Department of Pneumology, Gabriel Montpied University Hospital, 63003 Clermont-Ferrand, France.; Departement of Thoracic Surgery, Jean Perrin Cancer Center, 63011 Clermont-Ferrand, France; Department of Anatomy, College of Medicine, Université d'Auvergne, 63000 Clermont-Ferrand, France.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.